Health Daily - 05/01/2026

• The United Kingdom digital health market is expected to grow from about USD 15.46 billion in 2025 to USD 36.84 billion by 2030, representing a compound annual growth rate (CAGR) of ~18.9% over the forecast period.
• Growth is primarily driven by continued adoption of tele-healthcare services, mobile health (mHealth) apps, and advanced healthcare analytics, with tele-healthcare maintaining a significant share and analytics growing rapidly as providers embrace data-driven care models.
• Strong public-sector funding and NHS initiatives to digitalise care — including virtual wards, remote monitoring, and electronic patient records — are major catalysts for market expansion, along with streamlined regulatory pathways for digital therapeutics and connected devices.
• The market includes software, hardware, and services spanning chronic disease management, decision support, and workflow tools, with stakeholders such as hospitals, primary care practices, patients, and payers increasingly investing in connected digital solutions.

• The patient portal ManageMyHealth experienced a cybersecurity incident that allowed unauthorised access to personal health records of users, potentially affecting around 108,000–126,000 people out of roughly 1.8 million registered users.
• General practitioners (GPs) and health sector representatives said there’s been insufficient communication from ManageMyHealth about what exactly happened, when it was discovered, and what information was accessed, leaving clinicians and patients unsure about the breach’s scope.
• Health officials and critics have emphasized the need for timely, transparent information. including clear timelines, details of what data was compromised, and how affected individuals will be notified, to maintain trust in digital health systems.
• The Health Minister has commissioned a formal review into how ManageMyHealth and related public health agencies handled the breach, including assessing security practices and the adequacy of the response, with an aim to improve future transparency and data protection.

• CystoSmart™, an artificial intelligence software tool for detecting bladder tumors during endoscopic screening and surveillance, has received regulatory clearance from the Health Sciences Authority (HSA) in Singapore. This follows an earlier approval in Brazil and may help streamline further approvals in countries in the Access Consortium (e.g., Australia, Canada, UK).
• The AI tool is compatible with both flexible and rigid cystoscopes (including single-use scopes) used with standard white-light cystoscopy and is intended to aid clinicians by improving real-time and post-procedure detection of bladder tumors that might otherwise be missed.
• Clinical and technical evaluations indicate that CystoSmart™ has a sensitivity (true positive rate) of over 95% and a specificity (true negative rate) of over 98%, supporting its use as an assistive diagnostic aid.
• Early and accurate identification of bladder cancer can improve patient outcomes and reduce unnecessary biopsies and interventions, lessening physical, psychological, and resource burdens on patients and health systems.